FRONTIER EXPANDS CLINICAL NETWORK AND SHOWCASES qCTC PLATFORM IN JAPAN
Frontier’s Dr. Martin Burow and Dr. Chris Lee have just returned from Japan, where they expanded the company’s clinical network and accelerated discussions on the use of Frontier’s Circulating Tumour Cell (qCTC) platform within one of the world’s most advanced oncology health systems.
“The trip completely exceeded my expectations. I had not expected to have the opportunity to meet so many key opinion leaders in oncology face-to-face and to see their immediate enthusiasm and real interest in working with us,” said Dr. Lee.
Frontier’s qCTC technology was exceptionally well received, with Japan’s leading researchers and biotech innovators recognising its potential to transform cancer monitoring. The vision of real-time, personalised treatment resonated strongly, particularly given that many current approaches still rely on outdated or static monitoring techniques. qCTC was viewed as a breakthrough tool that could help redefine standards of care.
Looking ahead, Dr. Burow commented: “Several major centres want to integrate qCTC into both NIH-funded and domestic clinical trials, so we are very excited to begin this next phase of work in Japan. The whole trip could not have gone better.”
